SCHEMBL3974497

SCHEMBL3974497

COc1cc2nc(-c3ccc(Br)cc3)nc(C(N)Cc3ccccc3)c2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WHR1 P49842 2/20 0.49
SLC2A1 P11166 1/20 0.46
KDM4E B2RXH2 1/20 0.43
STAT6 P42226 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ABCG2 Q9UNQ0 4/20 0.41
ABCB1 P08183 3/20 0.41
ABCC1 P33527 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NTSR1 P30989 1/20 0.41
PDPK1 O15530 2/20 0.40
RPS6KB1 P23443 2/20 0.40
AKT1 P31749 2/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP1B1 Q16678 1/20 0.40
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3973240 0.84 HTT (0.43) NPSR1ABCG2MEN1KMT2ACYP1A1
SCHEMBL3972104 0.82 SLC2A1 (0.47) WHR1SLC2A1KDM4ESTAT6NPSR1
SCHEMBL3974309 0.81 NPC1 (0.55) ABCG2CYP1A1CYP1A2CYP1B1
SCHEMBL3972117 0.77 MEN1 (0.62) WHR1KDM4EMEN1KMT2ACYP1A2
SCHEMBL4238650 0.75 PDE5A (0.58) WHR1SLC2A1KDM4ESTAT6NPSR1
SCHEMBL4238649 0.75 WHR1 (0.50) WHR1SLC2A1KDM4ESTAT6NPSR1
SCHEMBL3976890 0.74 SLC2A1 (0.46) WHR1SLC2A1KDM4ESTAT6NPSR1
SCHEMBL24391696 0.74 WHR1 (0.68) WHR1KDM4ESTAT6NPSR1ABCG2
SCHEMBL3976324 0.71 SLC2A1 (0.56) WHR1SLC2A1KDM4ESTAT6NPSR1
SCHEMBL27599112 0.70 TLR9 (0.46) WHR1SLC2A1KDM4ESTAT6NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 WHR1 4569/4885SLC2A1 1107/4885KDM4E 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.